HeartBeam logo

HeartBeamNASDAQ: BEAT

Profile

Sector:

Healthcare

Country:

United States

IPO:

11 November 2021

Next earnings report:

20 March 2025

Last dividends:

N/A

Next dividends:

N/A
$74.40 M
-15%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-7%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 86 min ago
$2.79-$0.04(-1.33%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BEAT Latest News

HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Rob Eno - Chief Executive Officer Branislav Vajdic - President and Founder Tim Cruickshank - Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the HeartBeam Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization
businesswire.com17 October 2024 Sentiment: POSITIVE

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization.

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
prnewswire.com14 June 2024 Sentiment: POSITIVE

- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML - - 52% CRc (14 of 27 pts) observed in AUGMENT-102 trial of revumenib in combination with fludarabine-cytarabine in acute leukemia patients with R/R mNPM1, NUP98r or KMT2Ar - WALTHAM, Mass. , June 14, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from multiple combination trials of revumenib, the Company's potent, selective, small molecule menin inhibitor, in patients with acute leukemias.

HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias
businesswire.com20 May 2024 Sentiment: POSITIVE

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam's Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias.

HeartBeam, Inc. (BEAT) Q1 2024 Earnings Call Transcript
Seeking Alpha12 May 2024 Sentiment: POSITIVE

HeartBeam, Inc. (NASDAQ: BEAT) Q1 2024 Earnings Conference Call on May 9, 2024 at 4:30 PM ET with Company Participants Branislav Vajdic, Rob Eno, Rick Brounstein, and Brooks Hamilton, as well as Conference Call Participants Leo Carpio. Thank you for joining us for the HeartBeam First Quarter 2024 Financial Results Conference Call.

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
Business Wire09 April 2024 Sentiment: POSITIVE

HeartBeam showcases successful outcomes in utilizing its artificial intelligence technology to identify irregular heart rhythms.

BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023
InvestorPlace20 March 2024 Sentiment: NEGATIVE

HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.

HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript
Seeking Alpha20 March 2024 Sentiment: POSITIVE

HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript

HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time
Business Wire31 October 2023 Sentiment: POSITIVE

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time.

HeartBeam, Inc. (BEAT) Q2 2023 Earnings Call Transcript
Seeking Alpha13 August 2023 Sentiment: POSITIVE

HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

What type of business is HeartBeam?

BioTelemetry, Inc. is a leading medical technology company specializing in providing remote services in various areas of healthcare. The key focus is on remote monitoring of various vital signs of outpatient patients. The company was founded in 1994, with headquarters located in Malvern, Pennsylvania. BioTelemetry, Inc. provides remote cardiac monitoring, centralized laboratory services for clinical trials, remote blood glucose monitoring, and the manufacturing of original equipment that serves clients in the healthcare system and clinical research. The company operates in two reporting segments: Healthcare Segment and Research Segment.

What sector is HeartBeam in?

HeartBeam is in the Healthcare sector

What industry is HeartBeam in?

HeartBeam is in the Health Information Services industry

What country is HeartBeam from?

HeartBeam is headquartered in United States

When did HeartBeam go public?

HeartBeam initial public offering (IPO) was on 11 November 2021

What is HeartBeam website?

https://www.heartbeam.com

Is HeartBeam in the S&P 500?

No, HeartBeam is not included in the S&P 500 index

Is HeartBeam in the NASDAQ 100?

No, HeartBeam is not included in the NASDAQ 100 index

Is HeartBeam in the Dow Jones?

No, HeartBeam is not included in the Dow Jones index

When was HeartBeam the previous earnings report?

No data

When does HeartBeam earnings report?

The next expected earnings date for HeartBeam is 20 March 2025